Mr. Robert Steen reports

PHARMADRUG ANNOUNCES DIRECTOR APPOINTMENT AND RESIGNATION

Pharmadrug Inc. has appointed Zalman Goldman to the board of directors, subject to approval of the Canadian Securities Exchange.

Mr. Goldman is the founding director of Jacs Toronto and has spent 20-plus years in the world of addiction and recovery, and has used that time to try and make the city of Toronto a safer place when it comes to drug use and abuse. He has sat on the mayor's council on drug abuse and created dozens of programs over the years to assist families with the effects of addiction. Mr. Goldman is a pioneer in the recovery world, and he is thrilled to join the board of Pharmadrug and glad that it continues to make advancements in the health field, "I'm glad Pharmadrug has a role in making the world a safer place."

In connection with Mr. Goldman's appointment, the company also announces that Nickolai Vassev has resigned as a director, effective April 30, 2024. The board of directors would like to thank Mr. Vassev for his contributions to the company.

In connection with his appointment to the board, Mr. Goldman has been granted an option to acquire 500,000 shares, exercisable at five cents per share for a period of five years, subject to the policies of the Canadian Securities Exchange and the company's stock option plan.

About Pharmadrug Inc.

Pharmadrug is a specialty pharmaceutical company focused on the research, development and commercialization of controlled substances and natural medicines such as psychedelics and previously approved drugs. Pharmadrug owns 51 per cent of Sairiyo Therapeutics, a biotech company that specializes in researching and reformulating established natural medicines with a goal of bringing them through clinical trials and the associated regulatory approval process in the United States and Europe. Sairiyo is currently developing its patented reformulation of cepharanthine, a drug that has shown substantial third party validated potential for the treatment of infectious disease and rare cancers. Sairiyo is also conducting research and development in the psychedelics space for the treatment of non-neuropsychiatric conditions. Pharmadrug also owns 100 per cent of SecureDose Synthetics Inc., a pharmaceutical research and development company focused on the development of synthetic formulations of currently existing drugs for potential commercialization and distribution.

We seek Safe Harbor.